Status:
UNKNOWN
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Center for Malariology, Parasitology, and Entomology
Tulane University School of Public Health and Tropical Medicine
Conditions:
Plasmodium Falciparum Malaria
Plasmodium Vivax Malaria
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study assesses the effectiveness and feasibility of enhanced reactive case detection (RACD) targeting high-risk villages and forest workers for reducing Plasmodium falciparum and Plasmodium vivax...
Detailed Description
In the Greater Mekong Subregion (GMS), the risk of malaria infection is often due not to village-based transmission but rather to occupational and behavioral risk factors leading to exposure in forest...
Eligibility Criteria
Inclusion
- RACD:
- \- Inclusion Criteria
- Inclusion Criteria for index cases: Presented as a confirmed malaria case to an intervention health facility or village malaria worker, and lives in a village within a selected intervention health facility catchment area, or worked or spent at least one night at a forest or forest-fringe site in the past 30 days located within an intervention health facility catchment area
- Inclusion criteria for village residents: Lives in a village within a selected intervention health facility catchment area and in one of the five households closest to the residence of an index case of malaria
- Inclusion criteria for co-worker/traveler referral: Worked or traveled and spent at least one night in forest in past 30 days in same location within an intervention health facility catchment area as an index case of malaria
- Inclusion criteria for all participants: Willing and available to participate in the study
- Informed consent for participant under the age of 18 will be provided by the parent or guardian.
- \- Exclusion Criteria:
- Previous participation in the study as a result of any RACD event in the past 30 days.
- Individuals with suspected severe malaria or other severe illness (including those with symptoms of severe anemia, prostration, impaired consciousness, respiratory distress, convulsions, circulatory collapse, abnormal bleeding, jaundice or passing dark urine) will be excluded from the treatment component and referred to the nearest health facility for clinical assessment and treatment
Exclusion
Key Trial Info
Start Date :
September 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2021
Estimated Enrollment :
31443 Patients enrolled
Trial Details
Trial ID
NCT04416945
Start Date
September 20 2020
End Date
November 1 2021
Last Update
September 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Malariology, Parasitology, Entomology, Laos Ministry of Health
Vientiane, Laos